Update on melanoma and non-melanoma skin cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 12, 2011, Pages 1829-1832

  Zalaudek, Iris ^a   Whiteman, David ^b   Rosendahl, Cliff ^c   Menzies, Scott W ^d   Green, Adle C ^b   Hersey, Peter ^e   Argenziano, Giuseppe ^f  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

actinic keratosis; dermoscopy; epidemiology; melanoma; nevi; non melanoma skin cancer

Indexed keywords

ALPHA2 INTERFERON; B RAF KINASE INHIBITOR; DNA; INTERLEUKIN 6; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEGINTERFERON ALPHA2B; PROTEIN P53; RAS PROTEIN; SUNSCREEN; VEMURAFENIB;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ASSOCIATION; DNA DAMAGE; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; EPILUMINESCENCE MICROSCOPY; GENETIC ASSOCIATION; HUMAN; INTROSPECTION; MEDICAL RESEARCH; MELANOMA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PREDICTIVE VALUE; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING;

CONGRESSES AS TOPIC; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 82355164088     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.180     Document Type: Conference Paper

References (17)

1. Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J. Natl Cancer Inst. 95(11), 806-812 (2003). (Pubitemid 36798427)
2. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 24(5), 879-897 (2011).
3. Zalaudek I, Catricalà C, Moscarella E, Argenziano G. What dermoscopy tells us about nevogenesis. J. Dermatol. 38(1), 16-24 (2011).
4. Zalaudek I, Guelly C, Pellacani G et al. The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations. J. Invest. Dermatol. 131(2), 542-545 (2011).
5. Welch HG, Black WC. Overdiagnosis in cancer. J. Natl Cancer Inst. 102(9), 605-613 (2010).
6. Menzies SW, Emery J, Staples M et al. Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial. Br J. Dermatol. 161(6), 1270-1277 (2009).
7. Altamura D, Avramidis M, Menzies SW. Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch. Dermatol. 144(4), 502-506 (2008). (Pubitemid 351581107)
8. Argenziano G, Zalaudek I, Hofmann- Wellenhof R et al. Total body skin examination for skin cancer screening in patients with focused symptoms. J. Am. Acad. Dermatol. doi:10.1016/j. jaad.2010.12.0392011 (2011) (Epub ahead of print).
9. Agarwala SS, Lee SJ, Flaherty LE et al. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697). Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 3-7 June 2011. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 8505).
10. Eggermont AM, Suciu S, Santinami M et al.; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial. Lancet 372(9633), 117-126 (2008). (Pubitemid 351952257)
11. Lapouge G, Youssef KK, Vokaer B et al. Identifying the cellular origin of squamous skin tumors. Proc. Natl Acad. Sci. USA 108(18), 7431-7436 (2011).
12. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J. Invest. Dermatol. 115(2), 273-277 (2000). (Pubitemid 30637198)
13. Van der Pols JC, Williams GM, Pandeya N, Logan V, Green AC. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol. Biomarkers Prev. 15(12), 2546-2548 (2006). (Pubitemid 46048320)
14. Hughes MC, van der Pols JC, Marks GC, Green AC et al. Food intake and risk of squamous cell carcinoma of the skin in a community: the Nambour skin cancer cohort study. Int. J. Cancer 119(8), 1953-1960 (2006). (Pubitemid 44356857)
15. Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J. Am. Acad. Dermatol. 53(6), 966-972 (2005). (Pubitemid 41677321)
16. Zalaudek I, Giacomel J, Schmid K. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: a progression model. J. Am. Acad. Dermatol. doi:10.1016/j.jaad.2011.02.011 (2011) (Epub ahead of print).
17. Rosendahl C, Hansen C, Cameron A et al. Measuring performance in skin cancer practice: the SCARD initiative. Int. J. Dermatol. 50(1), 44-51 (2011).